Passage Bio, a developer of gene therapies for rare monogenic CNS diseases launched seven months ago, has licensed its sixth gene therapy from the University of Pennsylvania and its Gene Therapy Program (GTP), a preclinical treatment for Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A).